|
|
|
|
DiaMedBase ID |
|
DMPA082 |
|
Medicinal Plant
|
|
Astragalus (AS)
and Panax notoginseng (PNS) |
|
Plant part(s)
|
|
Whole
plant |
|
Objective |
|
To investigate the role and mechanism of
Astragalus (AS) and saponins of Panax notoginseng (PNS) in treating
type 2 diabetic macroangiopathy. |
|
Journal Source
|
|
Zhongguo
Zhong Yao Za Zhi,
2004; 29(3):264-266 |
|
Title
|
|
Effects of Astragalus and saponins of
Panax notoginseng on MMP-9 in patients with type 2 diabetic
macroangiopathy |
|
Authors
|
|
Liu
KZ, Li JB, Lu HL, Wen JK, Han M |
|
Address
|
|
Department of Endocrinology, The Third
Hospital of Hebei Medical University, Shijiazhuang 050051, China |
|
Abstract
|
|
To investigate the role and mechanism of
Astragalus (AS) and saponins of Panax notoginseng (PNS) in treating
type 2 diabetic macroangiopathy, 94 patients with type 2 diabetic
macroangiopathy were divided into two groups randomly: group treated
with Simvastatin and group treated with AS and PNS, compared with 40
healthy control subjects. Serum level of MMP-9 and lipid in patients
and healthy subjects were measured before and after treatment. The
serum levels of MMP-9, TG, TC, LDL-C, VLDL-C in patients with type 2
diabetic macroangiopathy were improved, while the levels of HDL-C were
decreased. Like Simvastatin AS and PNS had the function of reducing
MMP-9 and accommodating lipid metabolism. CONCLUSION: Besides
accommodating lipid metabolism, AS and PNS can also reduce the level
of serum MMP-9 soas to treat type 2 diabetic macroangiopathy. |
|
Diseases |
|
Disease Link |
|
DiaMedBase ID |
|
DMPAm083 |
|
Medicinal Plant
|
|
Astragalus membranaceus |
|
Plant part(s)
|
|
Roots |
|
Objective |
|
To
study the effects of Astragalus
polysaccharide (APS) on protein tyrosine phosphatase 1B (PTP1B) |
|
Journal Source
|
|
Acta Pharmacologica Sinica,
2005; 26(3):345 |
|
Title
|
|
Hypoglycemic effect of
Astragalus polysaccharide and its effect on PTP1B |
|
Authors
|
|
Yong WU2,3,
Jing-ping OU-YANG2,5, Ke WU2, Ya WANG2,
Yun-feng ZHOU2, Chong-yuan WEN4 |
|
Address
|
|
2Department of Pathophysiology, Medical
College of Wuhan University, Wuhan 430060, China;
3Department of Physiology, Hubei College of
Traditional Chinese Medicine, Wuhan 430060, China;
4Department of Endocrinopathic Sciences,
Renmin Hospital, Wuhan University, Wuhan 430060, China |
|
Abstract
|
|
Aim: To examine the effects of Astragalus polysaccharide (APS),
a component of an aqueous extract of Astragalus membranaceus
roots, on protein tyrosine phosphatase 1B (PTP1B), a negative
regulator of insulin-receptor (IR) signal transduction, and its
potential role in the amelioration of insulin resistance.
Methods: Ten-week-old fat-fed streptozotocin (STZ)-treated rats,
an animal model of type II diabetes mellitus (TIIDM), were treated
with APS (400 mg/kg po) for 5 weeks. Insulin sensitivity was
identified by the insulin-tolerance test. Further analyses on the
possible changes in insulin signaling occurring in skeletal muscle and
liver were performed by immunoprecipitation or Western blotting. PTP1B
activity was measured by an assay kit. Results:
The diabetic rats responded to APS with a significant decrease in
body weight, plasma glucose, and improved insulin sensitivity. The
activity and expression of PTP1B were elevated in the skeletal muscle
and liver of TIIDM rats. Thus the insulin signaling in target tissues
was diminished. APS reduced both PTP1B protein level and activity in
the muscle, but not in the liver of TIIDM rats. Insulin-induced
tyrosine phosphorylation of the IR β-subunit and insulin receptor
substrate-1 (IRS-1) were increased in the muscle, but not in the liver
of APS-treated TIIDM rats. There was no change in the activity or
expression of PTP1B in APS-treated normal rats, and blood insulin
levels did not change in TIIDM rats after treatment with APS.
Conclusion: APS enables insulin-sensitizing and hypoglycemic
activity at least in part by decreasing the elevated expression and
activity of PTP1B in the skeletal muscles of TIIDM rats. |
|
Diseases |
|
Disease Link |
|
